Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of Comparing the Maintenance Treatment of Apatinib, Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer

NCT03889626 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT03889626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03889626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of Comparing the Maintenance Treatment of Apatinib, Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Unknown status
Start date
March 22, 2019
Completion date
March 22, 2024
Enrollment
242 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

apatinib, capecitabine, digestive system neoplasms, gastrointestinal neoplasms, molecular mechanisms of pharmacological action, neoplasms, stomach diseases, stomach neoplasms